Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 1-O-[O-[N-(hydroxyacetyl)-?-neuraminosyl]-(2?3)-O-?-D-galactopyranosyl-(1?4)-?-D-glucopyranosyl]-ceramide
- Correlated keywords
- Glycolyl-neuraminyl-lactosylceramide HD3 GM HD-3 LLG1 LLG-1 NeuGcGM3 Hematoside Glycoloylganglioside Glycoloyl-GM3 GlycoloylGM3
- Product Overview:
N-glycolyl-Ganglioside GM3 (NeuGc-GM3) is a form of ganglioside GM3 that contains an N-glycolylated sialic acid (NeuGc). It is not biosynthesized in humans under baseline conditions due to a mutation in CMP-Neu5Ac hydroxylase (CMAH), which converts N-acetyl sialic acid to N-glycolyl sialic acid, but NeuGc can be taken up by human cells via the diet and incorporated into glycolipids, such as ganglioside GM3.{54575,60205} NeuGc-GM3 impairs differentiation and maturation of dendritic cells in vitro and reduces CD4 expression in non-activated T cells.{54575,60206} It increases the number of lung tumor nodules formed in a murine Lewis lung carcinoma model.{60207} It is found in a variety of human cancers, including breast and lung cancers, as well as pediatric cancers.{54575} Levels of NeuGc-GM3 are negatively correlated with the number of mature dendritic cells in patient-derived non-small cell lung cancer (NSCLC) tumor tissue.{60208} Anti-NeuGc-GM3 antibodies, able to destroy tumor cells in vitro, have been found in individuals without cancer but not in patients with NSCLC.{54575,60209} N-glycolyl-Ganglioside GM3 mixture contains ganglioside GM3 molecular species with primarily C22:0, C23:0, and C24:0 fatty acyl chain lengths. As this product is derived from a natural source, there may also be variations in the sphingoid backbone. [Matreya, LLC. Catalog No. 1553]
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.